Bridge­Bio shares go in­to melt­down mode as their lead PhI­II drug im­plodes at the fin­ish line

Bridge­Bio CEO Neil Ku­mar had all but re­served the cham­pagne to cel­e­brate the suc­cess of its big Phase III study for aco­ramidis, de­signed to sta­bi­lize transthyretin and slow or halt the pro­gres­sion of TTR amy­loi­do­sis. They had bought out full rights to the drug in late 2020 and bor­rowed the first $450 mil­lion of a $750 mil­lion loan, adding to a hefty debt load while con­fi­dent­ly pre­dict­ing a straight march to the FDA in 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.